Anne M Stevens1, Sami B Kanaan2, Kathryn S Torok3, Thomas A Medsger4, Maureen D Mayes5, John D Reveille5, Marisa Klein-Gitelman6, Ann M Reed7, Tzielan Lee8, Suzanne C Li9, Gretchen Henstorf10, Christine Luu2, Tessa Aydelotte2, J Lee Nelson11. 1. Seattle Children's Research Institute and University of Washington, Seattle. anne.stevens@seattlechildrens.org. 2. Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. University of Pittsburgh and Children's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 4. University of Pittsburgh, Pittsburgh, Pennsylvania. 5. University of Texas Health Science Center at Houston. 6. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois. 7. Duke University School of Medicine, Durham, North Carolina. 8. Stanford University, Stanford, California and Lucile Packard Children's Hospital, Palo Alto, California. 9. Hackensack University Medical Center, Hackensack, New Jersey. 10. Seattle Children's Research Institute, Seattle, Washington. 11. Fred Hutchinson Cancer Research Center and University of Washington, Seattle.
Abstract
OBJECTIVE: Systemic sclerosis (SSc) is a rare disease that is particularly uncommon in children. Specific HLA alleles have been associated with SSc in adults. This study was undertaken to investigate HLA class II alleles in juvenile-onset SSc. METHODS: DRB1, DQA1, and DQB1 alleles were determined by DNA-based HLA typing. Analyses were conducted comparing Caucasian patients with juvenile-onset SSc (n = 76) to healthy Caucasian controls (n = 581). RESULTS: Initial analyses focused on HLA class II associations previously reported in adult Caucasian patients with SSc. The frequency of DRB1*11 was not significantly increased in juvenile-onset SSc (22.4% of patients with juvenile-onset SSc versus 17.6% of controls; odds ratio [OR] 1.35, P = 0.34), nor were the specific DRB1*11:01 or *11:04 alleles. DQA1*05, a risk factor previously identified in adult men with SSc, was increased in patients with juvenile-onset SSc versus controls (57.9% versus 44.1%; OR 1.76, P = 0.027), as was DRB1*03 (34.2% versus 22.5%; OR 1.79, P = 0.031). Secondary analyses of all DRB1 allele groups revealed an association with DRB1*10 (10.5% of patients with juvenile-onset SSc versus 1.5% of controls; OR 7.48, P = 0.0002). As this is a new observation, correction was made for multiple comparisons of 13 different DRB1 allele groups; results nevertheless remained significant (P = 0.003). Also, a lower frequency of DRB1*01 was observed in patients with juvenile-onset SSc who were younger at disease onset (OR 0.06, P = 0.01) and in those with antibodies to topoisomerase (OR 0.14, P = 0.024). CONCLUSION: Associations of HLA alleles with juvenile-onset SSc differed from associations with SSc in women, but were similar to associations with SSc in men. Additionally, a novel association with DRB1*10 was observed in children. The greatest proportion of genetic risk of SSc is contributed by the HLA complex, and the current study reveals the importance of the association of HLA class II genes in juvenile-onset SSc.
OBJECTIVE:Systemic sclerosis (SSc) is a rare disease that is particularly uncommon in children. Specific HLA alleles have been associated with SSc in adults. This study was undertaken to investigate HLA class II alleles in juvenile-onset SSc. METHODS:DRB1, DQA1, and DQB1 alleles were determined by DNA-based HLA typing. Analyses were conducted comparing Caucasian patients with juvenile-onset SSc (n = 76) to healthy Caucasian controls (n = 581). RESULTS: Initial analyses focused on HLA class II associations previously reported in adult Caucasian patients with SSc. The frequency of DRB1*11 was not significantly increased in juvenile-onset SSc (22.4% of patients with juvenile-onset SSc versus 17.6% of controls; odds ratio [OR] 1.35, P = 0.34), nor were the specific DRB1*11:01 or *11:04 alleles. DQA1*05, a risk factor previously identified in adult men with SSc, was increased in patients with juvenile-onset SSc versus controls (57.9% versus 44.1%; OR 1.76, P = 0.027), as was DRB1*03 (34.2% versus 22.5%; OR 1.79, P = 0.031). Secondary analyses of all DRB1 allele groups revealed an association with DRB1*10 (10.5% of patients with juvenile-onset SSc versus 1.5% of controls; OR 7.48, P = 0.0002). As this is a new observation, correction was made for multiple comparisons of 13 different DRB1 allele groups; results nevertheless remained significant (P = 0.003). Also, a lower frequency of DRB1*01 was observed in patients with juvenile-onset SSc who were younger at disease onset (OR 0.06, P = 0.01) and in those with antibodies to topoisomerase (OR 0.14, P = 0.024). CONCLUSION: Associations of HLA alleles with juvenile-onset SSc differed from associations with SSc in women, but were similar to associations with SSc in men. Additionally, a novel association with DRB1*10 was observed in children. The greatest proportion of genetic risk of SSc is contributed by the HLA complex, and the current study reveals the importance of the association of HLA class II genes in juvenile-onset SSc.
Authors: P G Vlachoyiannopoulos; U G Dafni; I Pakas; M Spyropoulou-Vlachou; C Stavropoulos-Giokas; H M Moutsopoulos Journal: Ann Rheum Dis Date: 2000-05 Impact factor: 19.103
Authors: Giorgia Martini; Ivan Foeldvari; Ricardo Russo; Ruben Cuttica; Anne Eberhard; Angelo Ravelli; Thomas J A Lehman; Sheila Knupp Feitosa de Oliveira; Gordana Susic; Galina Lyskina; Dana Nemcova; Robert Sundel; Fernanda Falcini; Herman Girschick; Ana Paula Lotito; Antonella Buoncompagni; Flavio Sztajnbok; Sulaiman M Al-Mayouf; Ilonka Orbàn; Clodoveo Ferri; Balu H Athreya; Patricia Woo; Francesco Zulian Journal: Arthritis Rheum Date: 2006-12
Authors: Kenneth Scalapino; Thaschawee Arkachaisri; Mary Lucas; Noreen Fertig; David J Helfrich; Aldo V Londino; Virginia D Steen; Thomas A Medsger Journal: J Rheumatol Date: 2006-04-01 Impact factor: 4.666
Authors: L S Loubière; N C Lambert; M M Madeleine; A J Porter; M E Mullarkey; J M Pang; D A Galloway; D E Furst; J L Nelson Journal: Rheumatology (Oxford) Date: 2004-11-30 Impact factor: 7.580
Authors: Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille Journal: Ann Rheum Dis Date: 2009-07-12 Impact factor: 19.103
Authors: L R Wedderburn; N J McHugh; H Chinoy; R G Cooper; F Salway; W E R Ollier; L J McCann; H Varsani; J Dunphy; J North; J E Davidson Journal: Rheumatology (Oxford) Date: 2007-11-14 Impact factor: 7.580
Authors: J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett Journal: J Clin Invest Date: 1992-09 Impact factor: 14.808
Authors: Anne M Stevens; Kathryn S Torok; Suzanne C Li; Sarah F Taber; Theresa T Lu; Francesco Zulian Journal: Front Immunol Date: 2019-06-25 Impact factor: 7.561